Literature DB >> 7488057

Down-regulation of c-Myc and Max genes is associated to inhibition of protein phosphatase 2A in K562 human leukemia cells.

A Lerga1, B Belandia, M D Delgado, M A Cuadrado, C Richard, J M Ortiz, J Martín-Perez, J León.   

Abstract

Treatment of the human myeloid leukemia K562 cells with the protein phosphatase inhibitors okadaic acid or calyculin A resulted in down-regulation of both c-myc and max genes at the mRNA and protein levels. The extent of the down-regulation was similar for both genes and was dependent on the dose and on the treatment time. Interestingly, c-myc and max down-regulation was concomitant with apoptosis induced by okadaic acid and calyculin A in K562 cells. The expression of c-myc and max returned to control levels after the removal of okadaic acid from the media, although apoptosis was irreversible. These effects were observed at okadaic acid concentrations (15 nM) that inhibited the activity of protein phosphatase type 2A but not of phosphatase type 1. We conclude that the inhibition of protein phosphatase 2A is associated to decreased levels of c-Myc/Max heterodimers in K562 cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488057     DOI: 10.1006/bbrc.1995.2547

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Role of protein kinase activity in apoptosis.

Authors:  M F Lavin; D Watters; Q Song
Journal:  Experientia       Date:  1996-10-31

2.  Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.

Authors:  Eric C Hales; Steven M Orr; Amanda Larson Gedman; Jeffrey W Taub; Larry H Matherly
Journal:  J Biol Chem       Date:  2013-06-20       Impact factor: 5.157

3.  Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells.

Authors:  Qiaoli Zhao; Andreana N Assimopoulou; Sabine M Klauck; Harilaos Damianakos; Ioanna Chinou; Nadine Kretschmer; José-Luis Rios; Vassilios P Papageorgiou; Rudolf Bauer; Thomas Efferth
Journal:  Oncotarget       Date:  2015-11-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.